AMW is a specialty pharmaceutical company that specializes in biodegradable implants and offers patients and partners access to innovative medicines to ensure treatment compliance and enable cost-effective treatments. The company covers the entire value chain, from (co-)development to manufacturing and international marketing.
AMW has two approved products - implants that release goserelin and leuprorelin and are marketed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed under the trade name Leugon® by AMW's wholly owned subsidiary Endomedica GmbH. Based on its unique expertise in formulation development, the company works with pharmaceutical and biotech partners worldwide to develop and manufacture high-quality products and comprehensive product lifecycle solutions.
AMW is based in Warngau in the greater Munich area.
